University of Zurich
Zurich, 8091, Switzerland
NCT Number: NCT03287739
Upper limb recovery after stroke is highly predictable early after stroke. Nijland et al. showed that based on two simple clinical bedside tests - 'Shoulder Abduction' and 'Finger Extension' (the so called 'SAFE model' [Stinear et al., 2012]) - measured within the first 72 hours after stroke, ~87% of the patients could be correctly classified as either regaining or not regaining some dexterity (recoverers or nonrecoverers, respectively) (Nijland et al., 2010). This kind of information regarding the patients' functional prognosis allows proper discharge planning, setting realistic rehabilitation goals, and adequate patient information. However, the length of hospital stay after stroke has been decreasing. Therefore, knowledge is needed regarding the ability to make an accurate first prediction within the first 24 hours after stroke onset while using simple clinical bedside assessments. This would facilitate an earlier triage and with that, an accelerated and smooth transition of patients within the stroke care continuum. In addition, a first prediction within 24 hours poststroke has the potential to decrease health care expenses, as length of hospital stay after an acute stroke is ~30% of the total costs (i.e., direct and indirect costs) associated with stroke (Roger et al., 2012; Fattore et al., 2012).
The primary objective of aRISE is to determine the ability of the behavioral biometric impairments 'Shoulder Abduction' and 'Finger Extension' measured <24 hours poststroke to predict outcome of upper limb capacity 3 months after stroke. The secondary aim is to investigate the the added value of other simple clinical bedside tests for predicting outcome of upper limb capacity 3 months poststroke.
aRISE is a prospective longitudinal observational cohort study of 40 first-ever ischemic stroke patients, who will be assessed <24 hours, 7 days and 3 months after stroke onset.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Zurich, 8091, Switzerland
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Assessment of behavioral biometric impairments
Time frame: 3 months poststroke
Upper limb capacity
Time frame: 3 months poststroke
Upper limb motor function
Time frame: 3 months poststroke
Upper limb motor function
Time frame: 48 hours, 7 days, and 3 months poststroke
Forearm skeletal muscle electric activity
Time frame: 48 hours, 7 days, and 3 months poststroke
Upper limb range of motion patterns
Time frame: 48 hours, 7 days, and 3 months poststroke
Neurological functions
Time frame: 48 hours, 7 days, and 3 months poststroke
Sitting balance
Time frame: 48 hours, 7 days, and 3 months poststroke
Walking ability (independence)
Time frame: 48 hours, 7 days, and 3 months poststroke
Global disability
Time frame: 48 hours, 7 days, and 3 months poststroke
Patient-reported daily life upper limb use
Time frame: 3 months poststroke
Time frame: 48 hours, 7 days, and 3 months poststroke
Intensity of therapy based on charts
Time frame: 48 hours, 7 days, and 3 months poststroke
Serious Events (1. death; 2. life-threatening illness or injury; 3. in-patient or prolonged hospitalisation; 4. medical or surgical intervention to prevent life threatening illness; 5. led to fetal distress, death or a congenital abnormality or birth defect)
University of Zurich
Other
Acronym: aRISE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02425345
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT05589402
Bone Diseases, Brain Diseases
Harlingen, Texas, United States
View Trial DetailsNCT06750692
Brain Diseases, Cardiovascular Diseases
Afyonkarahisar, Turkey (Türkiye)
View Trial DetailsNCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial Details